BPC-157 and Blood Vessels: What the Published Research Says

Published August 22, 2026 · Artemis Labs

BPC-157 and blood vessels — answer capsule: Published research on BPC-157 and blood vessels is preclinical, meaning it was done in animals, in cell cultures, or on tissue kept alive in a lab dish. The most recent entry is Yildirim 2026 (PMID 42123221), which reported that BPC-157 relaxed segments of human artery in a laboratory tissue bath, and that the relaxation depended on the vessel’s inner lining and on a gas called nitric oxide. Earlier rat work (Amam 2018) tied BPC-157 to that same nitric oxide pathway, and cell-culture work (Huang 2015) measured readouts associated with the growth of new blood vessels. The 2026 study was a tissue-bath experiment on surgical tissue samples, not a clinical trial. There is no published Phase II or Phase III human efficacy trial of BPC-157 for any use.

Key findings

• Yildirim 2026 (PMID 42123221) reported concentration-dependent, endothelium-dependent, nitric-oxide-mediated relaxation of human internal mammary artery tissue ex vivo, meaning the tissue was removed from the body and studied in a lab bath. It was not a trial in living people.
• Amam 2018 (DOI: 10.3748/wjg.v24.i47.5366) linked BPC-157 to the nitric oxide pathway in a rat model, using drugs that block or feed that pathway.
• Huang 2015 (DOI: 10.2147/DDDT.S82030) reported angiogenesis readouts in cell culture, alongside raised growth-factor levels, in an alkali-burn wound model.
• Seiwerth 2018 (DOI: 10.2174/1381612824666180712110447) reviewed BPC-157 against the standard angiogenic growth factors researchers use as reference compounds.

What did the 2026 human tissue study actually find?

BPC-157 is a 15-amino-acid peptide first identified as part of a protein found in human gastric juice. It is studied for how tissue repairs itself in animal models, and blood vessels are one of the areas researchers keep returning to.

Yildirim and colleagues published the first human-tissue mechanism data in 2026. They worked with the internal mammary artery, a vessel in the chest that heart surgeons routinely harvest during bypass operations. Leftover segments are common research material: human, healthy, and otherwise discarded. The team mounted those segments in a tissue bath, a temperature-controlled chamber that keeps tissue alive and measures how tightly it squeezes or how much it loosens. When BPC-157 was added, the segments relaxed. Three details matter more than the headline.

Concentration-dependent means the response tracked the amount of peptide in the bath. More peptide, more relaxation, in a graded way. A graded response is harder to explain away as noise.

Endothelium-dependent means the response needed the endothelium, the single layer of cells lining the inside of every blood vessel. Researchers strip that lining from some segments and leave it on others. If the effect disappears without the lining, the lining is doing the work.

Nitric-oxide-mediated means the signal ran through nitric oxide, a short-lived gas the endothelium releases to tell the muscle in the vessel wall to loosen. It is one of the best-understood signals in vascular biology.

What does “ex vivo” mean, and why does it matter?

Ex vivo is Latin for “out of the living.” It describes an experiment on tissue taken from a living body and studied outside it. The tissue is real, human, and alive during the test. Everything around it is artificial.

That sets a hard boundary on what the Yildirim result can tell anyone. A piece of artery in a bath has no blood pressure, no heartbeat, no nervous system, no hormones arriving from elsewhere, and no liver or kidneys changing the peptide’s concentration over time. The researchers put a known amount of compound directly onto the tissue. In a living body, none of that holds.

The honest reading is narrow. In human vascular tissue, BPC-157 engaged a real and well-mapped signalling pathway. That is a mechanism observation, not evidence of an outcome in a person, and the study was not designed to produce one.

What is angiogenesis, and how has BPC-157 been studied for it?

Angiogenesis is the growth of new blood vessels from vessels that already exist. Every wound needs it, because new tissue cannot survive without a fresh blood supply bringing it oxygen.

Huang 2015 is the study most often cited here. It combined a live-animal alkali-burn wound model with laboratory cell work, and reported readouts tied to cell growth, cell migration, and angiogenesis in culture, along with raised levels of several growth factors: VEGF, EGF, and HGF. Growth factors are the body’s own signalling proteins that tell cells to divide, move, or build. Similar findings were reported in other preclinical models, including rectovaginal fistula repair (Baric 2016) and eye-condition models (Sikiric 2023). All of these readouts came from animals or from cells in dishes.

Vascular researchers already have reference compounds for this. VEGF and its relatives have been studied for decades as recognized drivers of new vessel growth, and newer candidates get measured against them. Seiwerth 2018 placed BPC-157 in that comparison. It is a review, meaning it summarizes other published work rather than running a new experiment, so its value is framing rather than fresh evidence.

What pathway do researchers think is involved?

The pathway most often named is the VEGFR2 / Akt / eNOS axis. Preclinical studies reported that BPC-157 raised levels of VEGF receptor 2, a docking point on the surface of endothelial cells. Signals from that receptor pass through Akt, a relay protein inside the cell, and end at eNOS, the enzyme that manufactures nitric oxide.

That is the same chain the 2026 human tissue result lands on, approached from the other end. Amam 2018 tested it in rats by co-treating with L-NAME, which blocks nitric oxide production, and L-arginine, the raw material the body uses to make it. Watching an effect shrink when a pathway is blocked and change when it is fed is standard evidence that the pathway is genuinely involved.

Researchers working on this pathway can review the analytical specifications of our BPC-157 research peptide, which ships as a lyophilized powder with a lot-specific certificate of analysis.

What the research does not show

There is no published Phase II or Phase III human efficacy trial of BPC-157 for any use. Every efficacy claim in circulation is extrapolated from animal studies or from tissue and cell experiments. Pilot human safety work using infusion is referenced in the review literature (Mendias 2026, Mayfield 2026), but safety pilots are not efficacy trials.

Three limits are specific to the vascular research. BPC-157 has a multi-pathway profile with no single defined receptor, no canonical binding assay separating a positive response from a null one, and no biomarker the field has converged on. Effect sizes also vary substantially with model, dose, route, and species. And the 2026 human tissue finding is a single study on surgical tissue samples; replication in independent laboratories has not been published.

Regulatory status is unsettled. BPC-157 is not an FDA-approved drug for any use. It was placed on an interim 503A compounding category in September 2023, removed from that list on September 27, 2024 after the nominator withdrew, and is now under Pharmacy Compounding Advisory Committee review. It is also on the WADA Prohibited List under Section S2, prohibited at all times. A tested athlete faces an anti-doping violation regardless of source.

Where to read more

For how these vascular findings connect to cardiac research models, see BPC-157 heart research. For how new vessel growth fits into repair studies, see BPC-157 wound healing research. Our fuller treatment of the 2026 preclinical record is in the 2026 preclinical foundation review.

Frequently asked questions

Does the 2026 study prove BPC-157 works on human blood vessels?

No. It reported that BPC-157 relaxed human artery tissue in a laboratory bath through the nitric oxide pathway. That is mechanism data from tissue outside a body. Showing an outcome in living people requires a controlled clinical trial, and none has been published.

What is the difference between ex vivo and in vitro?

Ex vivo studies use real tissue taken from a living organism and kept alive outside it. In vitro studies use isolated cells grown in a dish. Ex vivo tissue keeps its natural structure, with the vessel lining and muscle layers still arranged as they were.

Why is nitric oxide such a focus in this research?

Nitric oxide is the main signal the lining of a blood vessel uses to tell the vessel wall to loosen. Researchers have reliable tools to block it or supply its raw material, which makes it a pathway you can test rather than only observe. Amam 2018 and Yildirim 2026 both built their designs around that.

References

1. Yildirim et al. (2026). Endothelium-dependent, nitric-oxide-mediated relaxation of human internal mammary artery by BPC-157, ex vivo. PMID 42123221
2. Amam et al. (2018). BPC-157 and the nitric oxide pathway in a rat major venous occlusion and duodenal lesion model. World J Gastroenterol. DOI: 10.3748/wjg.v24.i47.5366
3. Huang et al. (2015). BPC-157 in alkali-burn wound healing in vivo, with proliferation, migration, and angiogenesis readouts in vitro. Drug Des Devel Ther. DOI: 10.2147/DDDT.S82030
4. Seiwerth et al. (2018). BPC-157 compared with standard angiogenic growth factors. DOI: 10.2174/1381612824666180712110447
5. Baric et al. (2016). Growth-factor upregulation in a rat rectovaginal fistula repair model. Life Sci. DOI: 10.1016/j.lfs.2016.02.029
6. Sikiric et al. (2023). BPC-157 in glaucoma and other ocular-condition animal models. Pharmaceuticals. DOI: 10.3390/ph16071052
7. Mendias CL, Awan TM. Sports Med. 2026. PMID 41966639
8. Mayfield CK, et al. Am J Sports Med. 2026. PMID 41476424

Methodology: this page draws on the Artemis Labs BPC-157 research record, a set of peer-reviewed studies and reviews each carrying a live PMID or DOI, last verified August 22, 2026. No claim appears here without a cited source.

All compounds sold by Artemis Labs are for laboratory research use only. Nothing on this page is medical advice, and no statement has been evaluated by the FDA.